Mitochondrial fatty acid β-oxidation is important for energy production, which is stressed by the different defects found in this pathway. Most of the enzyme deficiencies causing these defects are well characterized at both the protein and genomic levels. One exception is carnitine palmitoyltransferase I (CPT I) deficiency, of which until now no mutations have been reported although the defect is enzymatically well characterized. CPT I is the key enzyme in the carnitine-dependent transport across the mitochondrial inner membrane and its deficiency results in a decreased rate of fatty acid β-oxidation. Here we report the first delineation of the molecular basis of hepatic CPT I deficiency in a new case. cDNA analysis revealed that this patient was homozygous for a missense mutation (D454G). The effect of the identified mutation was investigated by heterologous expression in yeast. The expressed mutant CPT IA displayed only 2% of the activity of the expressed wild-type CPT IA, indicating that the D454G mutation is the disease-causing mutation. Furthermore, in patient's fibroblasts the CPT IA protein was markedly reduced on immunoblot, suggesting that the mutation renders the protein unstable.
CITATION STYLE
Ijlst, L., Mandel, H., Oostheim, W., Ruiter, J. P. N., Gutman, A., & Wanders, R. J. A. (1998). Molecular basis of hepatic carnitine palmitoyltransferase I deficiency. Journal of Clinical Investigation, 102(3), 527–531. https://doi.org/10.1172/JCI2927
Mendeley helps you to discover research relevant for your work.